• Please log in or register to access this feature.
You have full text access to this OnlineOpen article

Comparison of efficacy and safety between individualized and empiric dose regimen of amitriptyline in the treatment of major depressive episode

  1. GORAN S. MIHAJLOVIC phd1,
  2. DRAGAN R. MILOVANOVIC phd2,*,
  3. SLOBODAN M. JANKOVIC phd2

Article first published online: 3 NOV 2003

DOI: 10.1046/j.1440-1819.2003.01171.x

Issue

Psychiatry and Clinical Neurosciences

Psychiatry and Clinical Neurosciences

Volume 57, Issue 6, pages 580–585, December 2003

Additional Information

How to Cite

MIHAJLOVIC, G. S., MILOVANOVIC, D. R. and JANKOVIC, S. M. (2003), Comparison of efficacy and safety between individualized and empiric dose regimen of amitriptyline in the treatment of major depressive episode. Psychiatry and Clinical Neurosciences, 57: 580–585. doi: 10.1046/j.1440-1819.2003.01171.x

Author Information

  1. 1

    Psychiatric Clinic,

  2. 2

    Center for Clinical and Experimental Pharmacology, Clinical Hospital Center Kragujevac, Serbia, Yugoslavia

*Dr Dragan R. Milovanovic, Center for Clinical and Experimental Pharmacology, Zmaj Jovina 30, PO Box 179, 34000 Kragujevac, Yugoslavia. Email: piki@ptt.yu

Publication History

  1. Issue published online: 3 NOV 2003
  2. Article first published online: 3 NOV 2003
  3. Received 15 January 2003; revised 24 March 2003; accepted 6 April 2003.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (59K)

REFERENCES

  • 1
    Kessel JB, Simson GM. Tricyclic and tetracyclic drugs. In: KaplanHI, SadockBJ (eds). Comprehensive Textbook of Psychiatry. Williams & Wilkins, Baltimore, 1995; 2096–2112.
  • 2
    Potter WZ, Zavadil III AP, Kopin IJ, Goodwin FK. Single dose kinetics predicts steady-state concentrations on imipramine and desimipramine. Arch. Gen. Psychiatry 1980; 37: 314–320.
  • 3
    Timotijevic I, Zdravkovic M, Pokrajac M, Miljkovic B, Stojkovic M, Marinkovic O. Correlation of mono and combined amitriptyline/lithium therapy with therapeutic and side effects. Rom. J. Physiol. 1994; 31: 103–111.
  • 4
    Benet LZ, Oie S, Schwartz JB. Design and optimization of dosage regimens; pharmacokinetic data. In: HardmanJG, LimbirdLE, MolinoffPB, RuddonRW, GilmanAG (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, 1996; 1707–1792.
  • 5
    Jankovic SM, Timotijevic I, Mihajlovic GS, Djukic Dejanovic S. Comparison of two approaches to amitriptyline dose individualization. Eur. J. Drug Metab. Pharmacokinet. 1999; 24: 163–168.
  • 6
    Timotijevic I, Paunovic VR. [The Instruments of Clinical Assessment in Psychiatry.] Scientific Book, Belgrade, 1992 (in Serbian).
  • 7
    Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J. Clin. Psychopharmacol. 1994; 14: 230–240.
  • 8
    Corona GL, Cucchi ML, Frattini P et al. Aspects of amitriptyline and nortriptyline plasma level monitoring in depression. Psychopharmacology (Berl.) 1990; 100: 334–338.
  • 9
    Furlanut M, Benetelllo P, Spina E. Pharmacokinetic optimisation of tricyclic antidepressant therapy. Clin. Pharmacokinet. 1993; 24: 301–318.
  • 10
    Schulz P, Dick P, Blaschke TF, Hollister L. Discrepancies between pharmacokinetic studies of amitriptyline. Clin. Pharmacokinet. 1985; 10: 257–268.
  • 11
    Jankovic SM. Individualization of antibiotic dose regime in surgical patients. Specialist's thesis. Medical Faculty, University of Belgrade, 1996.
  • 12
    Barbui C, Hotopf M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomized controlled trials. Br. J. Psychiatry 2001; 178: 129–144.
  • 13
    Ellis PM, Smith DA. Treating depression: the beyondblue guidelines for treating depression in primary care. ‘Not so much what you do but that you keep doing it’. Med. J. Aust. 2002; 176 (Suppl.): S77–S83.
  • 14
    Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants:  efficacy,  safety,  and  cost  effectiveness. J. Clin. Psychiatry 1991; 52 (Suppl.): 23–33.
  • 15
    Skomedal T, Osnes JB, Johannessen SI, Lund PK, Aass H. Therapeutic drug monitoring with the help of serum concentration measurements. How are the analytical results distributed in a population? Tidsskr. Nor. Laegeforen 1993; 113: 2242–2246.
  • 16
    Ulrich S, Lauter J. Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression. Clin. Pharmacokinet. 2002; 41: 853–876.
  • 17
    Pidrman V, Krpalek P. Side effects of amitriptyline in relation to its plasma levels. Cesk. Psychiatrie 1998; 88: 106–112.
  • 18
    Vandel P, Bonin B, Leveque E, Sechter D, Bizouard P. Tricyclic antidepressant-induced extrapyramidal side effects. Eur. Neuropsychopharmacol. 1997; 7: 207–212.
View Full Article (HTML) Get PDF (59K)